# US 10,945,991 B2 · Use and pharmaceutical composition for liver fibrosis prevention and/or treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,991 B2
- Document ID: US10945991B2
- Status: Granted
- Kind: B2
- Application number: 16/173,243
- Filed: 2018-10-29
- Published: 2020-04-30
- Granted: 2021-03-16
- Earliest claimed: 2018-10-29
- Assignees: Cojet Biotech Inc.
- Applicants: Cojet Biotech Inc.
- Inventors: Yu-Lung Wang; Judy Chen
- Web page: https://patentgrep.com/patent/US10945991B2

## CPC

- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure discloses an extract of Antrodia cinnamomea and pharmaceutical application thereof. As confirmed by the researches of the present disclosure, said extract of Antrodia cinnamomea is able to decrease the activities of hepatic stellate cell and therefore obtain the efficacy of liver fibrosis prevention and/or treatment. Accordingly, the present disclosure discloses a novel pharmaceutical application of Antrodia cinnamomea and provides an alternative prevention and/or treatment regime of liver fibrosis for the field.

## Claims

### Claim 1

A method for preventing and/or treating liver fibrosis: comprising administering a subject in need an effective amount of Formula (I) compound:

### Claim 2 (depends on 1)

The method of claim 1, wherein the effective amount is sufficient to inhibit the activity of a stellate cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Formula (I) compound is formulated as a pharmaceutical composition; wherein the pharmaceutical composition further comprises a pharmaceutically acceptable additive.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pharmaceutical composition is formulated as tablet, capsule, injection, powder, granule, or oral solution.

### Claim 5 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable additive comprises: carrier, excipient, preservative, diluent, filler, binding agent, disintegrant, absorption accelerator, sweetener, or a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the effective amount is 0.02 to 2.0 g/60 kg body weight/day.